# A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

> **NCT04430855** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 68 (actual)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04430855
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2021-04-22
- **Final completion:** 2022-01-25
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04430855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04430855, "A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04430855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*